ARTICLE | Company News
AlphaRx, Select Therap deal
February 3, 2003 8:00 AM UTC
ALRX completed its previously announced acquisition of exclusive worldwide rights to Select's VT-1, a toxin that targets CD77 on tumor cells (see BioCentury, Nov. 18, 2002). The compound is in precli...